SLC22A1低表达与肝癌患者的不良预后相关:303例报告 |
| |
引用本文: | 王恕同,沈顺利,华赟鹏,陈斌,匡铭,李绍强,何强,彭宝岗.SLC22A1低表达与肝癌患者的不良预后相关:303例报告[J].南方医科大学学报,2015,35(10):1417. |
| |
作者姓名: | 王恕同 沈顺利 华赟鹏 陈斌 匡铭 李绍强 何强 彭宝岗 |
| |
摘 要: | 目的评估SLC22A1在肝癌患者中的表达及其对预后的影响。方法使用303例肝癌(HCC)和匹配的癌旁肝组织(ANLTs) 标本构建组织芯片并进行免疫组化染色(IHC),两名病理医生对SLC22A1的表达进行评分。评分范围为1到12分,总分>6为 高表达组,总分≤6为低表达组。分析SLC22A1表达量与患者的临床病理特征的关系。结果所有ANLTs的IHC评分均为12分, 肝癌中仅29例(9.6%)为12分。根据患者HCC的IHC评分将其分为两组:59%(180/303)为低表达组(评分≤6);41%(123/303) 为高表达组(评分>6)。低表达组的无瘤生存率(DFS)和总体生存期率(OS)均显著低于高表达组。低表达组的1、3、5年DFS分 别为43%,31%和27%,高表达组为58%,47%和43%。低表达组的1、3、5年OS分别为66%,38%和32%,高表达组为80%,57% 和50%。SLC22A1的低表达与肿瘤直径,BCLC分期,肿瘤分化和AFP水平相关(P<0.05)。SLC22A1低表达是影响总体生存 的独立预后因子(HR,1.454;95% CI,1.050~2.013)。结论SLC22A1低表达是肝细胞癌的恶性特征和潜在不良预后的标志。
|
Low expression of SLC22A1 is associated with a poor prognosis of hepatocellularcarcinoma: analysis of 303 patients |
| |
Abstract: | Objective To evaluate the association between SLC22A1 expression and the outcomes of hepatocellular carcinoma (HCC) patients. Methods A tissue microarray of 303 HCC and matched adjacent noncancerous liver tissues (ANLTs) were constructed. The expression of SLC22A1 was tested by immunohistochemistry (IHC) and scored by two pathologists according to a 12-score scale (a score>6 was defined as high expression, and a score≤6 as low expression). The correlation of SLC22A1 expression with the clinicopathological features and the patients’ outcome was analyzed. Results All the ANLTs had a IHC score of 12, as compared to only 29 (9.6%) of the HCC tissues. The patients were divided into 2 groups based on the IHC scores: 59% (180/303) in low expression group and 41% (123/303) in high expression group. The disease-free survival (DFS) rates and overall survival (OS) rates were significantly lower in low SLC22A1 expression group than in the high expression group. The 1-, 3-, and 5-year DFS rates were 43%, 31% and 27% in the low expression group, and were 58%, 47% and 43% in the high expression group, respectively. The 1-, 3-, and 5-year OS rates were 66%, 38% and 32% in low expression group, and were 80%, 57% and 50% in the high expression group, respectively. A low expression of SLC22A1 was positively correlated with the tumor diameter, BCLC stage, tumor differentiation, and AFP levels (P<0.05), and was an independent predictor of poor overall survival (HR=1.454; 95% CI, 1.050-2.013). Conclusion Down-regulation of SLC22A1 is a malignant feature and a potential prognostic marker of HCC.
|
| |
Keywords: | |
|
| 点击此处可从《南方医科大学学报》浏览原始摘要信息 |
| 点击此处可从《南方医科大学学报》下载免费的PDF全文 |
|